Search | Clinical Trials Finder

Conditions: Multiple Sclerosis
Interventions: Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more

Conditions: Hypertension
Interventions: tadalafil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Pyruvate Dehydrogenase Complex Deficiency
Interventions: Dichloroacetate (DCA), Placebo, Genotype; Drug · Other · Genetic
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more

Conditions: Healthy
Interventions: JNJ-70033093, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity
Interventions: IHBG-10, Placebo; Dietary Supplement
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Acquired Bleeding Disorder, Trauma
Interventions: eptacog alfa (activated), placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Alzheimer's Disease
Interventions: Placebo, Gantenerumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 30
States / cities: Sun City, Arizona • Tucson, Arizona • Costa Mesa, California + 27 more

Conditions: Thoracic Kyphosis
Interventions: Thoracic Mobilization, Light Touch Contact; Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Scar Prevention, Scar Reduction
Interventions: AZX100 Drug Product, Placebo; Drug
Lead sponsor: Capstone Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Austin, Texas

Conditions: Chronic Venous Leg Ulcers
Interventions: EPA+DHA, placebo; Dietary Supplement · Other
Lead sponsor: Ohio State University; Other
Eligibility: 55 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alzheimer's Disease
Interventions: MK-1167, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Hallandale, Florida • Decatur, Georgia • Savannah, Georgia

Conditions: Type 2 Diabetes
Interventions: dapagliflozin, placebo, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 111
States / cities: Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more

Conditions: Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 45 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 8
States / cities: San Francisco, California • San Jose, California • Stanford, California + 5 more

Conditions: Hematologic Diseases, Anaemia, Sickle Cell
Interventions: GSK4172239D, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more

Conditions: Intestinal Barrier Function
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Escondido, California • Greenbrae, California • Walnut Creek, California + 11 more

Conditions: Alzheimer's Disease
Interventions: Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg; Drug
Lead sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC; Industry
Eligibility: 50 Years to 88 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 219
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 170 more

Conditions: Fractures, Closed, Wounds and Injuries
Interventions: cefazolin, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Nausea
Interventions: Bremelanotide, Zofran, Placebo; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Malaria, Malaria,Falciparum
Interventions: PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline; Biological · Other
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 9 more

Conditions: Schizophrenia
Interventions: Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 34
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions: Erythropoietin, Sham Comparator; Drug · Other
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 24 Hours to 96 Days
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2000
U.S. locations: 9
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Conditions: Liver Cirrhosis
Interventions: BI 3802876, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Chandler, Arizona • Coronado, California • La Mesa, California + 21 more

Search by objective public record fields.

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Tadalafil in Subjects With Mild to Moderate Hypertension

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

Anti-psychotic Medication (New Use) Weight Loss Study

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

Can Mobilizations Applied to the Thoracic Spine Improve Oxygen Saturation Levels and Thoracic Kyphosis in E-Cigarette Smokers?

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

The Effect of Probiotic Intake on Intestinal Permeability in Healthy Adults

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Antibiotic Prophylaxis in Orthopaedic Traumatology

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)